Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
5.85
-0.05 (-0.85%)
At close: Nov 5, 2026, 4:00 PM EST
5.76
-0.09 (-1.54%)
After-hours: Nov 5, 2026, 7:30 PM EST
Emergent BioSolutions Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 649.1 | 742.9 | 1,044 | 1,049 | 1,118 | 1,774 | |
Revenue Growth | -17.72% | -28.81% | -0.54% | -6.10% | -36.99% | 12.45% |
Cost of Revenue | 367.3 | 375.6 | 732 | 795.1 | 827.4 | 980.4 |
Gross Profit | 281.8 | 367.3 | 311.6 | 254.2 | 290.1 | 793.2 |
Selling, General & Admin | 183.2 | 186.6 | 298.7 | 356.7 | 339.5 | 348.7 |
Amortization of Goodwill & Intangibles | 60.6 | 65.1 | 65.1 | 65.6 | 59.9 | 58.5 |
Operating Expenses | 244.1 | 251.7 | 363.8 | 422.3 | 399.4 | 407.2 |
Operating Income | 37.7 | 115.6 | -52.2 | -168.1 | -109.3 | 386 |
Interest Expense | -45.4 | -59.3 | -71 | -87.9 | -37.3 | -34.5 |
Other Non Operating Income (Expenses) | 76.7 | 54.2 | 11.9 | 6.4 | -11.7 | -3.7 |
EBT Excluding Unusual Items | 69 | 110.5 | -111.3 | -249.6 | -158.3 | 347.8 |
Merger & Restructuring Charges | -205.3 | -3.3 | -55.9 | -33.2 | -51.4 | - |
Impairment of Goodwill | - | - | - | -218.2 | -6.7 | -41.7 |
Gain (Loss) on Sale of Assets | -14.4 | - | 24.3 | 74.2 | - | - |
Asset Writedown | -12.2 | -12.2 | - | -306.7 | - | - |
Other Unusual Items | -77.1 | -12.2 | - | 2.3 | -2.6 | -2.9 |
Pretax Income | -240 | 82.8 | -142.9 | -731.2 | -219 | 303.2 |
Income Tax Expense | 20.7 | 30.2 | 47.7 | 29.3 | -7.4 | 83.7 |
Earnings From Continuing Operations | -260.7 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Net Income | -260.7 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Net Income to Common | -260.7 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Net Income Growth | - | - | - | - | - | -28.22% |
Shares Outstanding (Basic) | 52 | 54 | 53 | 51 | 50 | 54 |
Shares Outstanding (Diluted) | 52 | 57 | 53 | 51 | 50 | 54 |
Shares Change | -7.67% | 6.98% | 3.52% | 2.20% | -7.39% | 0.56% |
EPS (Basic) | -5.04 | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
EPS (Diluted) | -5.04 | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 |
EPS Growth | - | - | - | - | - | -28.52% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 188.4 | 156.8 | 35.8 | -257.9 | -149.9 | 96.1 |
Free Cash Flow Per Share | 3.64 | 2.77 | 0.68 | -5.04 | -2.99 | 1.78 |
Gross Margin | 43.41% | 49.44% | 29.86% | 24.23% | 25.96% | 44.72% |
Operating Margin | 5.81% | 15.56% | -5.00% | -16.02% | -9.78% | 21.76% |
Profit Margin | -40.16% | 7.08% | -18.26% | -72.48% | -18.93% | 12.38% |
Free Cash Flow Margin | 29.03% | 21.11% | 3.43% | -24.58% | -13.41% | 5.42% |
EBITDA | 125.7 | 211.4 | 56.6 | -43 | 15.7 | 504.2 |
EBITDA Margin | 19.36% | 28.46% | 5.42% | -4.10% | 1.41% | 28.43% |
D&A For EBITDA | 88 | 95.8 | 108.8 | 125.1 | 125 | 118.2 |
EBIT | 37.7 | 115.6 | -52.2 | -168.1 | -109.3 | 386 |
EBIT Margin | 5.81% | 15.56% | -5.00% | -16.02% | -9.78% | 21.76% |
Effective Tax Rate | - | 36.47% | - | - | - | 27.61% |
Revenue as Reported | 649.1 | 742.9 | 1,044 | 1,049 | 1,118 | 1,774 |